

**CURRICULUM VITAE  
FRIDA LEONETTI**

**Part I General Information**

**Full Name:** Frida Leonetti

**POSITION TITLE:** Associate Professor of Endocrinology at Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino

**Part II EDUCATION/TRAINING**

TYPE	Year	Institution	FIELD OF STUDY
University graduation	1974-1980	Sapienza University of Rome	Medicine and Surgery
Licensure	1980	Sapienza University of Rome	Licensure for medical clinical practice
Speciality	1980-1983	Sapienza University of Rome, Policlinico Umberto I	Endocrinology
Foreign experience	1985	Yale University, CT, USA	Fellowship in the Metabolic and Diabetes Unit – Director Prof. Ralph DeFronzo
Ph.D.	1986-1990	Sapienza University of Rome	Endocrinological and Metabolic Sciences
Qualification	2012	Sapienza University of Rome	National Scientific Qualification for Associate Professor (SC06D2, SSD MED13)
Qualification	2017	Sapienza University of Rome	National Scientific Qualification for Full Professor (SC06D2, SSD MED13)
Master	2020	Catholic University of Rome	Management Training Course in “Methodology and Instruments for healthcare Management in Complex Organization”

**Part III- Appointments**

**III A- Academic Appointment**

Start	End	Institution	Position
1990	1993	Sapienza University	Technician Assistant (VII functional level - Collaboratore Tecnico)
1994	2001	Sapienza University	Technician Assistant (VIII functional level - Funzionario Tecnico)



2001	ongoing	Sapienza University	PhD – “Dottorato di Ricerca in Scienze Endocrinologiche”.
2001	2005	Sapienza University	“Corso di laurea in Infermieristica” - Polo Didattico di Rieti
2000	2008	Sapienza University	Podologia d’urgenza – “Corso di Laurea Infermieristica nel Corso di Laurea di Podologia”
2004	2017	Sapienza University	Endocrinology in “Patologia Integrata III - Corso di Laurea in Medicina e Chirurgia (CCL”A”)” I Faculty (3 CFU)
2010	2012	Sapienza University	Endocrinology in “Patologia Integrata III - Corso di Laurea in Medicina e Chirurgia” (CCL”B”) I Facoltà
2013	ongoing	Sapienza University	Member of the Academic Board of the PhD Course in Endocrinological Sciences
2016	2016	University InCore (San Paulo, Brazil)	Member of The Judging Committee of Defense of a Doctoral Thesis (PhD)
2016	2016	University Campus Bio-medico, Rome	Member of The Judging Committee of Defense of a Doctoral Thesis (PhD)
2017	ongoing	Sapienza University Polo Pontino	Endocrinology and Metabolism in “Patologia Integrata III - Corso di Laurea in Medicina e Chirurgia (CL”E”),” Pharmacy and Medicine (3 CFU)

#### Part IV bis – Speaker, Chairman and Scientific Director experiences:

- **Invited Speaker and Chairman in more than 200 national and international congresses.**
- **Scientific Director of the following ECM courses:**
  1. Diabesità: terapia medica e chirurgica - Secondo tempo RES 373-158367, ROMA 24/06/2016
  2. Corso residenziale avanzato - monitoraggio continuo della glicemia, RES 373-245465, Roma 06/12/2018
  3. Come e perché intensificare la terapia nel diabete tipo 2 con le combinazioni a rapporto fisso. WEB 373-248384, WEBINAR 20/02/2019
  4. Corso residenziale avanzato monitoraggio continuo della glicemia. RES 373-252419, MILANO,07/05/2019
  5. Il cross-talk cuore-rene: fisiopatologia ed aspetti clinici RES 373-254924, Roma, 15/05/2019
  6. Terapia con analoghi del glp-1: quando e perchè - i fase RES 373-260249, Roma,21/05/2019
  7. Diabete Tipo 1: come è cambiato il trattamento insulinico? RES373–255254, Catania, 24/05/2019 - 25/05/2019
  8. Terapia con analoghi del glp-1: quando e perchè - I FASE. RES 373-261118, Milano 18/06/2019
  9. "Terapia con analoghi del glp-1: quando e perchè" \_I FASE", RES, 373 – 261431, Bologna, 27/06/2019
  10. Corretta gestione del paziente con diabete tipo 2 ad alto rischio CV \_I FASE, RES 373-26777, Milano, 09/10/2019
  11. Il cross-talk cuore-rene: fisiopatologia ed aspetti clinici. RES, 373 – 255066, Milano, 15/10/2019
  12. "Diabete Tipo 1: come è cambiato il trattamento insulinico?" RES, 373-260365, Milano, 25/10/2019 - 26/10/2019
  13. Terapia con analoghi del glp-1: quando e perchè - II FASE, RES, 373-260259, Roma, 29/10/2019
  14. Gestione del rischio globale del diabetico di tipo 2: un ruolo per i dpp4?" , RES,373-267573, Milano, 09/11/2019
  15. Il cross-talk cuore-rene: fisiopatologia ed aspetti clinici RES, 373 – 255091, Catania, 04/11/2019

16. Terapia con analoghi del glp-1: quando e perchè - II FASE. RES, 373 – 261129, Milano, 11/11/2019
17. Terapia con analoghi del glp-1: quando e perchè' \_II FASE", RES, 373 – 261447, Bologna, 19/11/2019
18. Gestione del rischio globale del diabetico di tipo 2: un ruolo per i dpp4? RES, 373-267561, Roma, 23/11/2019
19. Diabete Tipo 1: come è cambiato il trattamento insulinico?. RES, 373 – 281320, Roma, 30/01/2020-31/01/2020
20. Monitoraggio Continuo della Glicemia \_II FASE, RES, 373-281468, Roma, 13/02/2020
21. SGLT2 inibitori e progressione della malattia renale nel diabete tipo 2. RES 373-282608, Catania, 29/02/2020
22. Corso teorico-pratico volto alla promozione di una gestione condivisa (cardiologo-diabetologo) dei pazienti con diabete tipo 2 ad alto rischio CV. RES, 373 – 294121, Milano, 18/09/2020
23. Monitoraggio continuo della glicemia \_II FASE. RES, 373 – 294003, Milano, 02/10/2020
24. Diabete Tipo 1: come è cambiato il trattamento insulinico? RES373 – 293899, Bari, 16/10/2020-17/10/2020
25. Corso teorico-pratico volto alla promozione di una gestione condivisa (cardiologo/diabetologo) dei pazienti con diabete tipo 2 ad alto rischio CV. RES, 373 – 294080, Roma, 30/10/2020
26. Monitoraggio continuo della glicemia \_II FASE. RES, 373 – 293993, Catania, 06/11/2020
27. Corretta gestione del paziente con diabete tipo 2 ad alto rischio CV - II FASE, RES 373 – 267785. Roma, 12/11/2020
28. Corretta gestione del paziente con diabete tipo 2 ad alto rischio CV \_II FASE, RES 373-267779, Milano, 10/11/2020
29. SGLT2 inibitori e progressione della malattia renale nel diabete tipo 2. RES, 373-294028, Roma, 25/11/2020
30. WEBINAR - SID-AMD Regione Lazio - Il diabete nell'era del COVID-19: è tempo di domande, WEB, 373 – 318051, WEBINAR 29/05/2021
31. Corso SID - SIC: Diabete mellito tipo 2 e rischio CV: interazione fra diabetologi e cardiologi nella pratica clinica. RES, 373–326726, Roma, 05/11/2021
32. Corso Territoriale AMD-SID Lazio La rete diabetologica: se non ora quando? RES, 373–346823, Sabaudia, 28/05/2022
33. Congresso Regionale AMD/SID Lazio "Il diabete oggi: una malattia sempre più complessa" RES, 373-356806, Roma, 07/10/2022-08/10/2022

## Part V - Editorial Activity

2013	ongoing	Member of Editorial Board of “Journal of the Brazilian Medical Association”
2014	2018	Member of Editorial Board of SID journal “Il Diabete”
2015	2021	Associate Editor of “Endocrine”
1990	ongoing	Ad hoc reviewer mainly for “Nutrition, Metabolism, Cardiovascular Diseases”, “Endocrine” (NMCD), “Obesity Surgery”, “Metabolism”, “Diabetes Research”, “Journal of Clinical Endocrinology and Metabolism (JCEM)”, “Journal of Endocrinology Investigation (JEI)”, “Diabetes/Metabolism Research and Reviews”, “Obesity Research”, “Obesity”, “Internal and Emergency Medicine (IAEM)”, “European Journal of Clinical Nutrition (EJCN)”, “Obesity Research & Clinical Practice (ORCP)”, “Diabetes, Obesity and Metabolism (DOM)”.

**Part VI- Society memberships, Awards and Honors**

1982		AWARD: winner of a scholarship from the Ministry of Health for research in the field of social diseases carried out in the field of oncological diseases entitled: "Physiopathological and diagnostic aspects of hormone secretion in insulin-secreting tumors of the endocrine pancreas".
1984		AWARD: winner of a scholarship from the Ministry of Public Education for training activities at university-level foreign institutions in sector 7 - medical disciplines.
1986		AWARD: winner of an award from the Italian Society of Diabetology for research activities in the United States.
1992	ongoing	Member of Italian Society of Diabetes (SID)
2001	ongoing	Member of Italian Endocrinology Society (SIE)
2004	ongoing	Member del Direttivo DEM (Diabetes Endocrinologia and Metabolism)
2006	ongoing	Member of the Italian Obesity Society (SIO)
2007	2011	Member of the SIE Board of the Lazio section
2010	2012	Member of Scientific Committee of Italian Diabetes Society
2010	2016	Member of the SIO Board of the Lazio section
2011	2014	Member of Intersocietes SID-SIO Study Group on "Obesity, Diabetes and Bariaric Surgery"
2012	ongoing	EMA - Consultant of European Medicine Agency
2012	2018	Member of Mobbing Commission for "Ordine dei Medici" of Rome
2014	2016	Coordinator of Intersocietes SID-SIO Study Group on "Obesity, Diabetes and Bariaric Surgery"
2014	2016	Member of Teaching Committee of Italian Diabetes Society
2016	2020	Member of National Board of Italian Diabetes Society
2016	2020	President of the SIO Lazio section
2016	2020	EASD - Member of European Association Study of Diabetes
2018	2020	Coordinator of the Italian Diabetes Society Teaching Committee
2018	2020	Member of the Patronage Commission of Italian Society of Diabetes
2020	2022	President of the SID Lazio Regional Section
2020	ongoing	Member of the Scientific Committee of the Foundation of the Italian Society of Diabetes - Diabetes Research Onlus
2023	ongoing	Coordinator of SID Working Group "Obesity and Diabetes"

**PART VII -Funding information (grant as PI or I)**

<b>Year</b>	<b>Title</b>	<b>PROGRAM</b>
2002-2003	Progetti ISTITUTO SUPERIORE DI SANITA'	Prevenzione della patologia aterosclerotica nella sindrome metabolica
2003-2004	Progetti ISTITUTO SUPERIORE DI SANITA'	Genotipo e fenotipo obeso e danno metabolico associato: fattori di rischio, markers di patologia e nuove strategie terapeutiche.
2002-2003	Progetti di FACOLTA'	Spesa energetica, ossidazione lipidica e sensibilita' insulinica nel paziente obeso
2004/2005	Progetti di FACOLTA'	Effetto dell'insulina sulla secrezione della ghrelina nell'obesita' non complicata
2006/2007	Progetti di FACOLTA'	Diabete e comorbilita' nell'obesita' patologica trattata con differenti interventi di chirurgia bariatrica

2008/2009	RICERCHE DI ATENEO FEDERATO	Ruolo della visfatina nella fisiopatologia dell'obesita'
2008	PRIN	Assetto endocrino-metabolico, diabete e altre comorbilità nel paziente obeso prima e dopo calo ponderale ottenuto con diversi interventi di chirurgia bariatrica: studio della disposizione del grasso corporeo, secrezione e sensibilità insuliniche, dispendio energetico e ruolo degli ormoni gastrointestinali. (grant 34.295 euro)
2010/2011	PRIN	Nuovi aspetti della fisiopatologia del diabete mellito e potenziali applicazioni terapeutiche
2002-2003	Progetti di ATENEO	Ruolo della ghrelina e del ppy 3-36 nei pazienti sottoposti ad interventi di chirurgia bariatrica per via laparoscopica
2003	Progetti di ATENEO	Ruolo della ghrelina e del ppy 3-36 nei pazienti sottoposti ad interventi di chirurgia bariatrica per via laparoscopica
2004	Progetti di ATENEO	Chirurgia, obesità e diabete : modelli sperimentali e studio clinico pilota
2005/2006	Progetti di ATENEO	Chirurgia, obesità e diabete: Efficacia del bendaggio gastrico regolabile laparoscopico vs. terapia medica intensiva nei pazienti con obesità di grado I e diabete tipo 2: trial prospettico randomizzato
2007	Progetti di ATENEO	Caratterizzazione genetica del NIRAD (Non Insulin Requiring Autoimmune Diabetes)
2008	Progetti di ATENEO	Trattamento chirurgico del diabete e suoi meccanismi fisiopatologici
2009	Progetti di ATENEO	Sleeve gastrectomy versus terapia medica nel trattamento del diabete mellito di tipo 2
2010/2011	Progetti di ATENEO	La componente "osteometabolica" nelle complicanze correlate all' obesità: il diabete doppio.
2012	Progetti di ATENEO	Impact of laparoscopic sleeve gastrectomy on diabetic obese patients with stage 5 chronic kidney disease on dialysis
2014	Progetti di ATENEO	Ruolo della flora batterica intestinale nella regolazione dell' infiammazione e della fibrosi nella steatoepatite non alcolica (NASH)
2015	Progetti di ATENEO	Uso degli analoghi del GLP-1 in pazienti con obesità e diabete mellito tipo 2 prima della Sleeve Gastrectomy Laparoscopica: istologia epatica e valutazione biochimica (Grant 15.000 + assegno di ricerca 23.450)
2013-2016	Progetti AWARDS	Sapienza University Mortality and Morbidity Event Rate (SUMMER) study in Diabetes (Grant 60.000 euro)
2018-2020	European Society for Endoscopy Surgery Grant (3 M Study)	Malabsorption and Gut Microbiota profile changes after laparoscopic Mini-Gastric bypass vs Roux-en-Y Gastric bypass: a prospective multicenter comparative study (Grant 20.000 euro)
2021-2023	SAFE Erasmus Project	Undergraduate Medical University Module in Nutrition: Connecting health and nutrition to help reducing noncommunicable diseases PROJECT N° 21PCS0003 (the "PROJECT") (Grant 52.000 euro)

**Clinical Trials:**

<b>Name</b>	<b>Identification</b>	<b>Phase/ REAL LIFE</b>	<b>Titles</b>
TROPHIES	H9X-MC-B016	REAL LIFE	Studio prospettico, osservazionale, condotto nel mondo reale degli esiti sanitari con dulaglutide e liraglutide in pazienti affetti da diabete di tipo 2
DULA 4	H9X-MC-GBGL	Phase 3	“Studio randomizzato in doppio cieco a bracci paralleli su efficacia e sicurezza di dosi sperimentali di dulaglutide in aggiunta a metformina in pazienti con Diabete Mellito di tipo 2”
SURPASS-3	I8F-MC-GPGH	Phase 3	studio randomizzato, in aperto, di fase II, volto a confrontare l'effetto di LY3298176 rispetto all'insulina degludec titolata sul controllo glicemico nei pazienti affetti da diabete mellito 2
SELECT	EX9536-4388	Phase 3	Effetti di Semaglutide sugli esiti cardiovascolari in persone obese o in sovrappeso
SYNERGY-NASH	I8F-MC-GPHR	Phase 2	Studio randomizzato in doppio cieco, controllato con placebo di valutazione dell'efficacia e della sicurezza di tirzepatide rispetto al placebo in pazienti con steatoepatite non alcolica
SUSTAIN OPTIMIZE	NN9535-4801	Phase 3	Efficacia e sicurezza di semaglutide sottocutanea 2.0 mg assunta una volta alla settimana in aggiunta all'insulina glargine a dose ridotta vs insulina glargine titolata in partecipanti con diabete di tipo 2 e in sovrappeso.
REDEFINE 3	NN9838-4942	Phase 3	Sicurezza vascolare di cagrilintide 2,4 mg s.c. in combinazione con semaglutide 2,4 mg (cagrisema 2,4 mg/2,4 mg s.c.) una volta la settimana in partecipanti con obesità e malattia cardiovascolare accertata
SRMOUNT MMO	I8F-MC-GPIJ	Phase 3	A randomized, double-blind, placebo-controlled study to investigate the effect of Tirzepatide of the reduction of morbidity and mortality in adults with obesity.
REX	NN9068-4740	REAL LIFE	Uno studio prospettico, non interventistico, a braccio singolo, volto ad indagare il controllo glicemico a lungo termine in pazienti con diabete di tipo 2, che iniziano Xultophy® (IDegLira) nella reale pratica clinica in Italia (Real-World Evidence Xulthophy).
GLIMPLES	GLp-1rafor sIMPLification in DiabetES	REAL LIFE	“Effectiveness of glucagon-like peptide-1 receptor agonists for therapeutic simplification in patients with type 2 diabetes. A real-world Italian multicenter study”
PEG		REAL LIFE	Valutazione dell'appropriatezza terapeutica sulla base del fenotipo del paziente con diabete di tipo 2: auto-analisi della pratica clinica ambulatoriale

GOLDEN AGE	TRS-2019-00002051	REAL LIFE	Intraclass safety and efficacy comparison among SGLT-2 inhibitors in elderly patients with type 2 diabetes. A pragmatic, phase IV, multicenter, open-label, randomised controlled trial.
INTENSE		REAL LIFE	Real world effectiveness of Lixisenatide and other intensification therapy in the management of type 2 diabetic patients uncontrolled with basal insulin
AID	A2581053	Phase 4	A multicenter, randomized, open label study to evaluate the efficacy and safety of atorvastatin versus simvastatin in type 2 diabetic subject with Hypercholesterolemia
INSAX	NN8022-4241	REAL LIFE	In market utilization of Liraglutide Used for weight management in Europe: a retrospective medical record review study
GLUCODAY	Multicenter Italian Study	REAL LIFE	Continuous subcutaneous glucose monitoring in diabetic patients
GENFIEV	SID Study	REAL LIFE	Metabolic syndrome in subjects at High risk for type 2 diabetes: the genetic, physiopathology and evolution of type 2 diabetes study
Equality1	SID-AMD Study	REAL LIFE	Quality of life and treatment satisfaction in adults with type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections
GISIR	Group of Italian Scientists of Insulin Resistance	REAL LIFE	Impact of lowering the criterion for impaired fasting glucose on identification of individuals with insuline resistance. The GISIR database
TOSCA	SID Study NCT0070856	REAL LIFE	Addition of either Pioglitazone or Sulfonylurea in type 2 diabetic patients inadequately controlled with metformine alone
GOLDEN AGE	SID Study TRS-2019-00002051	REAL LIFE	Intraclass safety and efficacy comparison among SGLT-2 inhibitors in elderly patients with type 2 diabetes. A pragmatic, phase IV, multicenter, open-label, randomised controlled trial.

### Part VIII- Research Activities

Keywords	Brief description
<b>Hypoglycemia</b> <b>Insulinomas</b> <b>Glucose Clamp</b> <b>Indirect Calorimetry</b> <b>Liver cirrhosis</b> <b>Monitoring Continuous Glucose</b> <b>Diabetes</b>	<p>At the beginning of my research I investigated a possible correlation between function and structure in the <b>neoplastic cells of the endocrine pancreas</b> (especially in insulinomas), developing several diagnostic (for example by somatostatin) and localization (calcium-stimulated selected celiac-tripode angiography) tests for these tumors. With the application of the <b>artificial pancreas</b> (BIOSTATOR, Miles) and subsequently through the use of the "<b>glucose clamp</b>" technique directly learned in the United States from its creator Prof. Ralph DeFronzo at Yale University School of Medicine, New Haven, CT, U.S.A, I have been able to evaluate the metabolic alterations in <b>hypoglycaemic syndromes</b> (both in organic and reactive ones) to then broaden the study of insulin action to syndromes characterized by significant <b>insulin resistance</b> such as <b>liver cirrhosis, type 2 diabetes, uncomplicated and pathological obesity, metabolic syndrome with cardiovascular risk factors</b>.</p> <p>At the same time, I acquired the techniques for the "in vivo" study of the energy expenditure and oxidation of the various substrates, associating the application of <b>indirect calorimetry</b> with other metabolic studies. <b>Liver cirrhosis</b> and liver transplantation have been one of the</p>



<b>Uncomplicated Obesity</b>	first sectors in which I applied the techniques acquired abroad, thus demonstrating the full normalization of metabolic parameters in liver transplanted cirrhotic patients.
<b>Epicardial Adipose Tissue</b>	At the same time I applied myself to glycemic monitoring in decompensated diabetic patients, contributing to the improvement of the first <b>glucose continuous monitoring (GLUCODAY)</b> .
<b>Bariatric Surgery</b>	Studies on oxidative metabolism and the evaluation of energy expenditure allowed me to refine my knowledge on the role of aerobic and non-aerobic <b>physical exercise</b> on the ability to use substrates by skeletal muscle in type 2 <b>diabetes mellitus and obesity</b> . The interest has also involved some aspects of nutrition in the light of the new peptides identified in the literature having a role on the hypothalamic centers of hunger and satiety, produced by adipose tissue and the upper gastrointestinal tract in the regulation of energy expenditure and eating behavior . The interests therefore extended from the simply overweight patient to the " <b>uncomplicated</b> " obese and to the <b>obese and super-obese diabetic patient with/without metabolic syndrome</b> . Precisely the studies on the "uncomplicated" obese patient, therefore free from confounding factors such as hypertension, diabetes or dyslipidemia, have allowed me to highlight <b>the role of obesity "per se"</b> in the context of cardiovascular risk and sensitivity insulin. The different distribution of adipose tissue and above all the study of <b>epicardial adipose tissue (EAT)</b> let me to identify the different secretory pattern of adipocytes and the importance of epicardial fat in insulin resistance and cardiovascular risk.
<b>Adipochines</b>	
<b>Incretines</b>	
<b>VLCKD</b>	
<b>Diabetes</b>	
<b>Diabetes remission</b>	
<b>NAFLD</b>	
<b>Microbiota</b>	
<b>Covid-19</b>	
<b>Diabetes Therapy</b>	<p>On this basis I focused my attention on obesity and treatment through <b>bariatric surgery</b> as a study model to highlight the metabolic and cytokine changes in the significant weight loss that is obtained with these morbidly obese patients with/without diabetes and/or metabolic syndrome, highlighting the changes in the most relevant <b>adipokines</b> such as adiponectin, leptin, visfatin and later also <b>gastrointestinal hormones</b> such as ghrelin, GLP1, GIP and obviously insulin secretion/sensitivity as well as energy expenditure. At that point, my research was oriented towards studying the new bariatric surgery interventions in people with diabetes: <b>Sleeve Gastrectomy</b> per se and versus <b>Gastric-bypass/One Anastomotic Gastric-bypass</b> and partial/total <b>remission of type 2 diabetes</b>. Study of surrogate indices in insulin secretion (HOMA-B) and in insulin sensitivity (HOMA-IR) have been than conducted in large cohort of patients. Adipokines (leptin, adiponectin, resistin, visfatin) and gastrointestinal hormones (ghrelin, GLP-1, GIP) have been measured before and after the different surgical operations at short, medium and long follow-up.</p> <p>New therapies for obesity have been than investigated from highly hypocaloric diets (especially ketogenic diets, <b>VLKCD</b>) to pharmacological ones, from sibutramine to current GLP1 analogues such as liraglutide 3 mg, semaglutide, toward GIP/GLP1-ra such tirzepatide.</p> <p>The main interest therefore fell on type 2 diabetes mellitus, from partial or complete remission after bariatric surgery to <b>incretins and gliflozins</b>, new insulins in pre-established combinations with short, medium and long-term follow-up.</p> <p>The same formulations have also been the subject of several <b>clinical trials</b> (phases 2 and 3) in the context of non-bariatric patients but affected by excess weight and type 2 diabetes (<b>diabetes</b>) and also in the absence of diabetes.</p> <p>Bariatric surgery allowed me to several studies through the possibility of studying the effect of weight loss on several aspects of obesity including the <b>ectopic adipose tissue</b> such as, for example, presence of adipocytes in the liver. Infact, the indices of liver function in <b>NAFLD and NASH</b> were validated by comparing with liver tissue obtained by biopsy obtained during the surgical interventions in the obese patients with/without diabetes. Another field</p>

	<p>of my interest has been the use of surgery induced weight-loss to assess <b>microbiota changes</b> and its correlations with metabolic alterations.</p> <p>Furthermore, the results of my research have contributed to a highly topical topic and to the center of international debates among the leading experts in the sector, especially on the role of bariatric surgery in general and of the various bariatric operations on the improvement and sometimes <b>resolution of diabetes mellitus</b> in patients with moderate and severe obesity.</p> <p>Recently, I improved the continuous glucose monitoring applying the new <b>continuous blood glucose monitoring systems</b> (pilot study of the ASL Latina company for FlashLibre1).</p> <p><b>COVID-19 pandemia:</b> during the covid-19 pandemic my research is focused on the study of predictive factors of the greater severity of the virus infection in the most fragile patients such as diabetics and the obese people. I investigated <b>Epicardial Adipose Tissue</b> assessed through the <b>chest CT</b> performed to diagnose Covid-19 pneumonia by publishing the data in time to be able to use it in subsequent pandemic waves in order to choose the best treatment at the beginning of the infection.</p>
--	--

### Part IX- Social Activities (third mission)

Year	typology	Activity
2016	ShortFilmFestival	FILMDIPESO I edition “Food, Nutrition, Behavioral Disorders and Obesity”
2018	ShortFilmFestival	FILMDIPESO II edition “Food, Nutrition, Behavioral Disorders and Obesity”
2019	ShortFilmFestival	FILMDIPESO III edition “Food, Nutrition, Behavioral Disorders and Obesity”
2021	ShortFilmFestival	FILMDIPESO IV edition “Food, Nutrition, Behavioral Disorders and Obesity”
2016-2021	High School	Organization of courses to improve healthy life style in order to prevent chronic non communicable diseases in Latin.
2023-ongoing	Sapienza University	Member of Working Group for Third mission activity at the DSBMC of the Sapienza University

### Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
<b>Papers (international)</b>	<b>158</b>	<b>Scopus</b>	<b>1982</b>	<b>2023</b>
<b>Papers (national)</b>	<b>17</b>			
<b>Books [scientific] Number of chapters</b>	<b>21</b>			
<b>Books [teaching] Number of chapters</b>	<b>6</b>			

<b>Total Impact factor</b>	<b>662,09</b>	<b>Scopus</b>
<b>ScopusTotal Citations</b>	<b>8348</b>	<b>Scopus</b>
<b>Average Citations per Product</b>	<b>52,83</b>	<b>Scopus</b>
<b>Hirsch (H) index</b>	<b>45</b>	<b>Scopus</b>
<b>Normalized H index*</b>	<b>1,09 (1,18**)</b>	<b>Scopus</b>

\*H index divided by the academic seniority from the 1<sup>st</sup> publication in 1982 (41 years).

\*\* including three maternity periods

### **Part X– Selected Publications**

**List of the publications selected for the evaluation. For each publication report authors, title, reference data, journal IF (if applicable), citations, press/media release (if any).**

1 Ridola L, Capoccia D, Guarisco G, Riggio O, **Leonetti F** (2022). Non-invasive tests for fibrosis detection: still in search for the best way. HEPATOBILIARY SURGERY AND NUTRITION, vol. 11, p. 920-923, ISSN: 2304-3881, doi: 10.21037/hbsn-22-466

IF (year of publication): 8; IF (2022 inCites): 8. Cit: 0

2 Barchetta I, Lubrano C, Cimini FA, Dule S, Passarella G, Dellanno A, Di Biasio A, **Leonetti F**, Silecchia G, Lenzi A, Cavallo MG (2023). Liver fibrosis is associated with impaired bone mineralization and microstructure in obese individuals with non-alcoholic fatty liver disease. HEPATOLOGY INTERNATIONAL, vol. 17, p. 357-366, ISSN: 1936-0533, doi: 10.1007/s12072-022-10461-1

IF (year of publication): 6,6; IF (2022 inCites): 6,6. Cit: 0

3 De Maio F., Boru Cristian, Avallone M., Velotti N., Bianco D. M., Capoccia D., Greco F., Guarisco G., Nogara M., Sanguinetti M., Verrastro O., Capaldo B., Musella M., Raffaelli M., Delogu G., Silecchia G., **Leonetti F.** (2021). Characterization of gut microbiota in patients with metabolic syndrome candidates for bariatric/metabolic surgery: preliminary findings of a multi-center prospective study. DIABETES RESEARCH AND CLINICAL PRACTICE, vol. 180, p. 1-10, ISSN: 0168-8227, doi: 10.1016/j.diabres.2021.109079

IF (year of publication): 8,1; IF (2022 inCites): 5,1. Cit: 1

4 Guarisco G., Fasolo M., Capoccia D., Morsello G., Carraro A., Zuccala P., Marocco R., Del Borgo C., Pelle G., Iannarelli A., Orlando E., Spagnoli A., Carbone I., Lichtner M., Iacobellis G., **Leonetti F.** (2021). Blood glucose and epicardial adipose tissue at the hospital admission as possible predictors for COVID-19 severity. ENDOCRINE, ISSN: 1355-008X, doi: 10.1007/s12020-021-02925-5

IF (year of publication): 2.0 ; IF (2022 inCites): 2.0 . Cit: 4

5 Guarisco G, **Leonetti F** (2020). Covid-19 and diabetes. When a pandemia cross another pandemia. EATING AND WEIGHT DISORDERS, ISSN: 1590-1262, doi: 10.1007/s40519-020-00958-9  
IF (year of publication): 3,0; IF (2022 inCites): 2,9. Cit: 5

6 Coccia F, Testa M, Guarisco G, Bonci E, Di Cristofano C, Silecchia G, **Leonetti F**, Gastaldelli A, Capoccia D. (2020). Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity. ENDOCRINE, vol. 67, p. 569-578, ISSN: 1355-008X, doi: 10.1007/s12020-019-02155-w -  
IF (year of publication): 2,3 ; IF (2022 inCites): 2,0. Cit: 7

7 Barchetta I, Cimini F A, Chiappetta C, Bertocchini L, Ceccarelli V, Capoccia D, Gaggini M. Di Cristofano C, Della Rocca C, Silecchia G, **Leonetti F**, Lenzi A, Gastaldelli A, Cavallo M. G. (2020). Relationship between hepatic and systemic angiopoietin-like 3, hepatic Vitamin D receptor expression and NAFLD in obesity. LIVER INTERNATIONAL, vol. 40, p. 2139-2147, ISSN: 1478-3223, doi: 10.1111/liv.14554  
IF (year of publication): 5,8; IF (2022 inCites): 6,7. Cit: 19

8 Capoccia D, Guida A, Coccia F, Guarisco G, Testa M, **Leonetti F**, Silecchia G (2019). Weight Regain and Diabetes Evolution After Sleeve Gastrectomy: a Cohort Study with over 5&nbsp;Years of Follow-Up. OBESITY SURGERY, vol. 30, p. 1046-1051, ISSN: 0960-8923, doi: 10.1007/s11695-019-04350-0  
IF (year of publication): 4,1; IF (2022 inCites): 2,9. Cit: 9

9 Coccia F., Testa M., Guarisco G., Di Cristofano C., Silecchia G., **Leonetti F.**, Gastaldelli A., Capoccia D. (2019). Insulin resistance, but not insulin response, during oral glucose tolerance test (OGTT) is associated to worse histological outcome in obese NAFLD. NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, vol. 30, p. 106-113, ISSN: 0939-4753, doi: 10.1016/j.numecd.2019.08.001  
IF (year of publication): 4,2; IF (2022 inCites): 3,9. Cit: 16

10 D'Onofrio L., Pieralice S., Maddaloni E., Mignogna C., Sterpetti S., Coraggio L., Luordi C., Guarisco G., Leto G., **Leonetti F.**, Manfrini S., Buzzetti R. (2021). Effects of the COVID-19 lockdown on glycaemic control in subjects with type 2 diabetes: the glycalock study. DIABETES, OBESITY AND METABOLISM, ISSN: 1462-8902, doi: 10.1111/dom.14380  
IF (year of publication): 6,4; IF (2022 inCites): 5,8. Cit: 32

11 Capoccia D, Coccia F, Guarisco G, Testa M, Rendina R, Abbatini F, Silecchia G, **Leonetti F** (2018). Long-term metabolic effects of laparoscopic sleeve gastrectomy. OBESITY SURGERY, vol. 28, p. 2289-2296, ISSN: 0960-8923, doi: 10.1007/s11695-018-3153-8  
IF (year of publication): 3,6; IF (2022 inCites): 2,9. Cit: 20

12 Del Chierico F, Abbatini F, Russo A, Quagliariello A, Reddel S, Capoccia D, Caccamo R, Corradini S, Nobili V, De Peppo F, Dallapiccola B, **Leonetti F**, Silecchia G, Putignani L (2018). Gut microbiota markers in obese adolescent and adult patients: Age-dependent differential patterns. FRONTIERS IN MICROBIOLOGY, vol. 9, ISSN: 1664-302X, doi: 10.3389/fmicb.2018.01210 - IF (year of publication): 4,2; IF (2022 inCites): 5,2. Cit: 112

13 Anastasi E, Capoccia D, Granato T, Silecchia G, Rizzello Mario, Porpora MG, Frati L, Angeloni A, **Leonetti F** (2016). Implementing the risk of ovarian malignancy algorithm adding obesity as a predictive factor. ANTICANCER RESEARCH, vol. 36, p. 6425-6429, ISSN: 0250-7005, doi: 10.21873/anticanres.11240 IF (year of publication): 1,9; IF (2022 inCites): 2,0. Cit: 3

14 Anastasi E, Capoccia D, Granato T, Viggiani V, Tartaglione S, Manganaro L, Angeloni A, **Leonetti F** (2016). Assessing the association between 25-OH vitamin D levels and ROMA score in a population of obese women. JOURNAL OF BIOLOGICAL REGULATORS & HOMEOSTATIC AGENTS, ISSN: 0393-974X IF (year of publication): 1,4; IF (2022 inCites): 3,2. Cit: 6

15 **Leonetti F**, Campanile FC, Coccia F, Capoccia D, Alessandrini L, Puzziello A, Coluzzi I, Silecchia G (2015). Very Low-Carbohydrate Ketogenic Diet Before Bariatric Surgery: Prospective Evaluation of a Sequential Diet. OBESITY SURGERY, vol. 25, p. 64-71, ISSN: 0960-8923, doi: 10.1007/s11695-014-1348-1 IF (year of publication): 3,3; IF (2022 inCites): 2,9. Cit: 46

16 Capoccia D, Coccia F, Guida A, Rizzello M, De Angelis F, Silecchia G, **Leonetti F** (2015). Is type 2 diabetes really resolved after laparoscopic sleeve gastrectomy? Glucose variability studied by continuous glucose monitoring. JOURNAL OF DIABETES RESEARCH, vol. 2015, ISSN: 2314-6745, doi: 10.1155/2015/674268 IF (year of publication): 2,4; IF (2022 inCites): 4,3. Cit: 9

Firma



Rome, 25/07/2023